Clinical Trial

Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma

Study acronym: TREMENDOUS-2
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase II, single-arm, multicentre study, assessing the efficacy and safety of durvalumab and tremelimumab with lenvatinib in participants with unresectable HCC.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-13
Trial Details
NCT Number NCT07081633
Lead Sponsor AstraZeneca
Conditions Hepatocellular Carcinoma
Enrollment 114 participants
Start Date 2025-08-05
Primary Completion 2026-11-30 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-12